Pharmacy Compounding — Conditions for Exemption
Exempts drugs compounded by a licensed pharmacist or physician for an identified individual patient from new-drug approval, adequate-directions-for-use labelling, and cGMP — provided a set of conditions is met. Added to the FD&C Act in its current form by the Drug Quality and Security Act of 2013.
What this does not cover
stated in the document's own scope- Covers patient-specific compounding by a licensed pharmacist or physician; compounding without a patient-specific prescription under cGMP is the outsourcing-facility route in §503B.
- Provides exemptions from three named requirements when its conditions are met; it does not exempt compounding from state pharmacy law or from USP compounding standards adopted by the state.
- Does not authorise compounding essentially copies of commercially available drugs on a regular basis, nor compounding drugs on the withdrawn-or-removed list.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
Section 503A of the Federal Food, Drug, and Cosmetic Act is the statutory basis for traditional pharmacy compounding. It exempts a drug compounded by a licensed pharmacist or licensed physician for an identified individual patient from three requirements that otherwise apply to drugs: new-drug approval, the "adequate directions for use" labeling requirement, and cGMP — provided a defined set of conditions is met. Those conditions include compounding pursuant to a valid prescription, using bulk substances that meet specified criteria, not compounding drugs that appear on a withdrawn-or-removed list, and not compounding regularly or in inordinate amounts copies of commercially available drugs.
Scope & applicability
Compounding pharmacies and physicians preparing patient-specific preparations. A 503A compounder is regulated principally by its state board of pharmacy; FDA retains authority over adulteration and misbranding but does not apply cGMP.
Legal basis & how it acquires force
Section 503A is part of the Federal Food, Drug, and Cosmetic Act. Its current, enforceable form comes from the Drug Quality and Security Act of 2013, which removed constitutionally problematic advertising-related language that had earlier left the section’s status uncertain. A compounded drug that meets all of §503A’s conditions is exempt from the three named requirements; one that does not meet them loses the exemption and is treated as it otherwise would be under the Act. For a §503A pharmacy, day-to-day oversight rests substantially with the state board of pharmacy.
Document structure
| Part | Covers |
|---|---|
| Prescription condition | Compounding for an identified individual patient based on a valid prescription order |
| Qualified compounder | Compounding by a licensed pharmacist or licensed physician |
| Bulk drug substances | Substances complying with a monograph, on an FDA list, or otherwise meeting stated criteria |
| Withdrawn/removed and copies limits | Not compounding drugs on the withdrawn-or-removed list, nor essentially copies of marketed drugs |
| Exemptions granted | The exemptions from new-drug approval, adequate-directions-for-use labeling, and cGMP |
Key requirements
- Compounding performed by a licensed pharmacist or physician, per a valid prescription for an identified patient
- Bulk substances comply with the statutory sourcing conditions
- Not essentially a copy of a commercially available drug product
- Not a drug appearing on the FDA withdrawn/removed-for-safety list
- Compliance with applicable USP compounding chapters as adopted by the state
Implementation tips
- Map every condition of the exemption to a procedure and a record — the exemption is only as good as the evidence that each condition held
- Track the 503A bulks list and the "difficult to compound" list; both change and both are enforcement triggers
- Where volume grows past patient-specific work, model the 503B path deliberately rather than drifting across the line
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
Section 503A defines traditional, patient-specific compounding, while its companion §503B defines the outsourcing-facility category for compounding without patient-specific prescriptions under cGMP. In practice, USP compounding standards — General Chapters <795>, <797>, and <800> — supply the operational detail, and these acquire force largely through adoption by state boards of pharmacy, which are the primary regulators of §503A pharmacies rather than FDA.
FD&C Act §503A: frequently asked questions
Quick answers to common questions about FD&C Act §503A.
What does FD&C Act §503A exempt a compounded drug from?
When its conditions are met, §503A exempts a drug compounded by a licensed pharmacist or physician for an identified individual patient from new-drug approval, the adequate-directions-for-use labeling requirement, and cGMP.
Who primarily regulates a §503A compounding pharmacy?
State boards of pharmacy have the primary day-to-day oversight of traditional §503A pharmacies. FDA retains authority under the Act, and USP compounding chapters generally apply through state adoption.
What gave §503A its current enforceable form?
The Drug Quality and Security Act of 2013, which removed the advertising-related language that had earlier rendered the section’s status uncertain, leaving §503A enforceable as it now stands.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.